Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
8
×
deals
8
×
life sciences
national blog main
biotech
boston blog main
national top stories
san francisco blog main
boston top stories
san francisco top stories
cancer
national
novartis
startups
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
editas medicine
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
biogen
cancer immunotherapy
gene editing
gene therapy
ipo
What
bio
gene
roundup
crispr
medicines
car
develop
editing
life
millions
new
science
talk
therapy
years
abbvie
access
acquisitions
advanced
alliance
announced
approval
available
bails
based
becker
big
billions
biogen’s
biopharmaceutical
biosciences
biotech
brand
bridgebio
capacity
capital
cas
cell
ceo
cheaper
Language
unset
Current search:
crispr
×
deals
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
